 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Clinical Assistant Professor, Department of Pharmacy, Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Assistant Professor, Department of Pharmacy, Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center
with Added Qualifications in Infectious Diseases, Associate Professor, Department of Pharmacy, Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center
Reprints: Staci M Lockhart PharmD BCPS, College of Pharmacy, University of Oklahoma Health Sciences Center, 1110 N. Stonewall, Rm. 206, Oklahoma City, OK 73117-5040, fax 405/271-6430, stacilockhart{at}ouhsc.edu
OBJECTIVE: To evaluate the clinical significance of interactions between anticonvulsant and antiretroviral agents and provide recommendations regarding their concurrent use.
DATA SOURCES: A PubMed search (1966 to April 2003) was conducted using individual anticonvulsant and antiretroviral drug names and the following key search terms: anticonvulsant, antiepileptic, antiretroviral, protease inhibitor, and pharmacokinetic. Abstracts from scientific meetings that pertained to drug interactions were manually reviewed.
STUDY SELECTION AND DATA EXTRACTION: All articles identified by the PubMed search were examined. Articles and abstracts from scientific meetings with relevant information were included.
DATA SYNTHESIS: Six case reports were identified that describe interactions between anticonvulsant agents and protease inhibitors. In several reports, carbamazepine serum concentrations increased by approximately two- to threefold with concurrent ritonavir, resulting in carbamazepine-related toxicity. Carbamazepine was also associated with loss of viral suppression when combined with indinavir. Phenytoin serum concentrations were decreased with nelfinavir in a patient who developed recurrent seizures. The effect of ritonavir on phenytoin was variable; a 30% reduction in phenytoin serum concentration occurred in one patient, while no apparent change was observed in another. Interactions with nonnucleoside reverse-transcriptase inhibitors are poorly characterized because existing data involve concurrent protease inhibitor therapy. The utility of newer anticonvulsant agents is explored. Experience with newer anticonvulsant agents in 2 patients at our site is also described.
CONCLUSIONS: Limited data exist regarding interactions between anticonvulsant and antiretroviral agents. Valproic acid and newer anticonvulsant agents may provide useful alternatives to first-generation agents. Clinicians need to be diligent when monitoring for anticonvulsant–antiretroviral interactions because of the potential for toxicity, loss of seizure control, and incomplete viral suppression.
Key Words: anticonvulsants, antiretrovirals, drug interactions, pharmacokinetics
Published Online, January 23, 2004. www.theannals.com, DOI 10.1345/aph.1D309
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-04-012-H02
This article has been cited by other articles:
|
|
 |
|
  M. Dickson, T. J. Bramley, C. Kozma, D. Doshi, and M. F. T. Rupnow Potential drug-drug interactions with antiepileptic drugs in Medicaid recipients Am. J. Health Syst. Pharm., September 15, 2008; 65(18): 1720 - 1726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ji, B. Damle, J. Xie, S. E. Unger, D. M. Grasela, and S. Kaul Pharmacokinetic Interaction Between Efavirenz and Carbamazepine After Multiple-Dose Administration in Healthy Subjects J. Clin. Pharmacol., August 1, 2008; 48(8): 948 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lin, M J. Tucker, and M. J Rieder Increased Adverse Drug Reactions to Antimicrobials and Anticonvulsants in Patients with HIV Infection Ann. Pharmacother., September 1, 2006; 40(9): 1594 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E Bates and R. J Herman Carbamazepine Toxicity Induced by Lopinavir/Ritonavir and Nelfinavir Ann. Pharmacother., June 1, 2006; 40(6): 1190 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Berns and N. Kasbekar Highly Active Antiretroviral Therapy and the Kidney: An Update on Antiretroviral Medications for Nephrologists Clin. J. Am. Soc. Nephrol., January 1, 2006; 1(1): 117 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Krikorian and D. C. Rudorf Drug-Drug Interactions and HIV Therapy: What Should Pharmacists Know? Journal of Pharmacy Practice, August 1, 2005; 18(4): 278 - 294. [Abstract] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
